Abbott Completes Exact Sciences Acquisition, Removing Key Uncertainty but Shifting Focus to Integration

What happened

Abbott Laboratories announced the completion of its acquisition of Exact Sciences on March 23, 2026, as per a PRNewswire release that emphasizes leadership in cancer screening and diagnostics. This move directly addresses Abbott's declining Diagnostics segment, which fell 4.5% ex-FX in 2025, as highlighted in the DeepValue report, where the deal was a critical but uncertain catalyst for growth reset. Prior to this, the report noted the acquisition remained 'proposed' as of March 9, 2026, with closing risks and a Q2 2026 timeline, making this early completion a positive surprise. The PR's optimistic language portrays this as a strategic win, but it downplays the significant challenges ahead, including integrating Exact's assets and managing increased debt. Now, Abbott must prove it can deliver the promised Diagnostics growth while maintaining its Medical Devices momentum amidst ongoing Libre quality concerns.

Implication

The completion of the Exact Sciences acquisition removes a key overhang on Abbott's stock, as it was a primary uncertainty in the investment thesis, potentially supporting near-term price appreciation. However, Abbott now faces approximately $20 billion in additional borrowings, increasing leverage and requiring disciplined financial management to avoid strain on balance sheet flexibility. Success depends on reversing the Diagnostics decline through Exact's cancer screening assets, which must offset post-COVID softness and challenging conditions in China, as noted in the DeepValue report. Medical Devices, particularly CGM with $7.6B in 2025 sales, remain the growth anchor, but any expansion of Libre quality issues beyond the current correction could erode this advantage. In the medium term, investors must monitor integration progress and early growth metrics in Diagnostics to assess whether the acquisition delivers on its promises or becomes a costly misstep.

Thesis delta

The investment thesis shifts from anticipating the Exact Sciences closing to evaluating post-acquisition integration and growth delivery, as the deal's completion eliminates regulatory and timing risks that were a key downside boundary. This strengthens the base case scenario where Diagnostics returns to positive organic growth, but it raises the bar for execution, with focus now on Abbott's ability to leverage Exact's assets and manage increased debt. Investors should reassess based on upcoming financial reports and integration updates, as failure to achieve Diagnostics stabilization could shift fundamentals toward the bear case despite the closure.